Research and Markets: the Obama Administration and the Pharmaceutical Industry - Overview of the 2009 Recovery Act and the

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/bab4ec/the_obama_administ) has announced the addition of the "The Obama Administration and the Pharmaceutical Industry - Overview of the 2009 Recovery Act and the 2010 Federal Budget" report to their offering.

President Obama has made healthcare reform one of his administrations top priorities. Towards this goal, several billion dollars have been provided through the Recovery Act and 2010 Budget for initiatives that are intended to make the US healthcare system safer and more cost-effective.

These include:

  • conducting comparative effectiveness research trials to help physicians and patients make more informed decisions at the point-of-care;
  • adopting health information technologies, such as ePrescribing, telemedicine and electronic medical records (EMR);
  • expanding Medicaid and strengthening Medicare by focusing on program integrity issues;
  • promoting more affordable drug options by expediting the approval of generic drugs and opening the market to consumers who would like to buy drugs from neighboring countries.

Healthcare reforms like these are all going to have a significant impact on the pharmaceutical industry's bottom line. This report discusses the upcoming and proposed reforms in detail, and includes information on how these changes will impact the pharmaceutical industry in the US.

Reasons to Purchase

Use this report to:

  • Learn how the Recovery Act of 2009 and the Fiscal Year 2010 Federal Budget will be used to enact change to the current US Healthcare System
  • Understand the 4 key areas of focus for healthcare reform highlighted by the Obama Administration and their impact on the pharmaceutical industry
  • Gain insights into how the pharmaceutical industry should approach the challenges that will ensue with comparative effectiveness research (CER)
  • Understand the advantages and barriers to Health IT, as well as its impact on the pharmaceutical industry
  • Find out how the current budget proposal could affect pharmaceutical drug pricing & project safety, along with changes to the government sponsored programs Medicare & Medicaid
  • Benefit from our conclusions and future outlook to best support your understanding and key decisions around the potential changes to the pharmaceutical industry as a result of US healthcare reform

Key Topics Covered:

Executive Summary

Introduction

  • The American Recovery and Reinvestment Act of 2009 - Funding Highlights of Interest to the Pharmaceutical Industry
  • The Fiscal Year 2010 Federal Budget - Funding Highlights of Interest to the Pharmaceutical Industry
  • Comprehensive Reform of the US Healthcare System - Planned Healthcare System Reforms

Comparative Effectiveness Research

  • Introduction to CER
  • Implications and Impact on the Pharmaceutical Industry
  • What Approach Should the Pharmaceutical Industry Take?

Health Information Technology (IT)

  • Advantages to HIT Adoption
  • Barriers to HIT Adoption
  • Impact on the Pharmaceutical Industry

Drug Costs and Improved Medical Product Safety

  • The Budget Proposal

Medicare and Medicaid

  • Expand Coverage to Low Income Individuals
  • Strengthen Medicare Part D Program Integrity

Outlook for the Pharmaceutical Industry

Appendix

For more information visit http://www.researchandmarkets.com/research/bab4ec/the_obama_administ



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   United States  North America

INDUSTRY KEYWORDS:   Health  Pharmaceutical  Professional Services  Other Professional Services

MEDIA:

Logo
 Logo

Suggested Articles

Monday, Bernstein analysts echoed what many were probably thinking about Novo Nordisk’s Rybselsus price: “Finally we can stop talking about it.”

Low interest rates and strong stock valuations are two top reasons why U.S. drugmakers are on the move for deals.

Despite a 45% premium offered to Allergan investors through the AbbVie buyout, one investor is suing to block the deal.